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doi:10.1016/j.jtcvs.2006.08.104bjective: Fixed pulmonary hypertension is a contraindication for cardiac trans-
lantation because of the increased risk of donor heart failure. We sought to
etermine whether left ventricular assist devices improve fixed pulmonary hyper-
ension in cardiac transplant candidates to enable safe cardiac transplantation.
ethods: Thirty-five consecutive cardiac transplant candidates (age 56  6 years,
8.5% were men) with fixed pulmonary hypertension (5.1  2.6 Wood units)
esistant to medical treatment received a left ventricular assist device as a bridge to
ransplantation. Three left ventricular assist device systems were used (pulsatile
lood flow: Novacor [World Heart Inc, Oakland, Calif] n  8; continuous blood
ow: MicroMed DeBakey [MicroMed Technology Inc, Houston, Tex] n  24,
uraHeart [Terumo Heart Inc, Ann Arbor, Mich] n  3). Right-sided heart catheter
ata were obtained before left ventricular assist device implantation at 3-day and
-week follow-ups. Clinical data and complications were recorded.
esults: Before left ventricular assist device implantation, the pulmonary vascular
esistance was 5.1  2.8 Wood units. Values were comparable in patients receiving
ulsatile (5.1  3.4 Wood units) or continuous blood flow left ventricular assist
evices (5.1  2.7 Wood units, P  .976). Left ventricular assist device implan-
ation decreased pulmonary vascular resistance at 3-day (2.9  1.3 Wood units,
 .0001) and 6-week (2.0  0.8 Wood units, P  .0001) follow-ups compared
ith before implantation. This effect was independent of the type of left ventricular
ssist device system used (3-day follow-up: pulsatile flow: 3.2  1.3 Wood units vs
ontinuous flow: 2.7  1.2 Wood units; P  .310 and 6-week follow-up: pulsatile
ow: 1.9  0.9 Wood units vs continuous flow: 2.1  0.8 Wood units; P  .905).
wenty-four patients had successful bridges to transplantation (69%, mean time on
eft ventricular assist device 210  83 days), and 11 patients died before transplan-
ation (31%, mean time on left ventricular assist device 67  30 days). The 1-year
urvival after transplantation was 95%.
onclusion: Left ventricular assist devices decrease fixed pulmonary hypertension
n cardiac transplant candidates and allow patients to overcome a contraindication
or cardiac transplantation. Therefore, left ventricular assist devices should be
onsidered in all cardiac transplant candidates with fixed pulmonary hypertension.
 
he prevalence of congestive heart failure is continuously increasing in the
Western world.1 Despite continuous advances of medical therapy for con-
gestive heart failure, cardiac transplantation is the most effective treatment
or patients with end-stage heart failure.2
Pulmonary hypertension (PH) is a risk factor for early and late death after cardiac
ransplantation. The reason for this is the unacceptably high risk of acute donor
ight-sided heart failure immediately after implantation.3-7 There is consensus that
he risk of death after cardiac transplantation is increased in patients with pulmonary
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CSPascular resistance (PVR) greater than 2.5 Wood units
WU), if PVR cannot be decreased by pharmacologic inter-
entions (fixed PH).8,9 Various pharmacologic agents
ave been evaluated for their ability to decrease PVR in
hese patients.10 Pharmacologic agents tested include so-
ium nitroprusside, inhaled nitric oxide, phosphodiesterase
nhibitors, urapidil, prostaglandins (PGE1 and PGI1), and
evosimendan.10-14 However, even by combining these phar-
acologic agents, PH cannot be significantly decreased in
any of these patients. No safe and efficient treatment can
e offered to those patients with end-stage heart failure
nd fixed severe PH today. Left ventricular assist devices
LVADs) have been reported to reduce PH in patients
ith terminal heart failure. We are the first to study this
opic in a prospective fashion and to compare pulsatile
nd continuous flow LVADS.15-17
In this prospective study we report on our experience
ith the treatment strategy of improving fixed PH in cardiac
ransplant candidates by means of LVAD implantation and
ubsequent orthotopic cardiac transplantation.
aterials and Methods
atients
uring the study period, 242 cardiac transplant candidates were
dmitted to our hospital. Of those, 72 patients received an LVAD.
ndication for LVAD implantation was terminal heart failure with-
ut fixed PH in 36 patients (50%), destination therapy in 1 patient
1%), and terminal heart failure with fixed PH (3.5 WU) in 35
atients (49%). The 35 consecutive patients with terminal heart
ailure and fixed PH entered this prospective study. To qualify, all
atients had to fulfill institutional inclusion criteria for terminal
eart failure and had to have fixed PH unresponsive to maximum
edical treatment. With the exception of fixed PH, patients had to
e suitable for cardiac transplantation. The study was approved by
he institutional review board, and all patients gave their written
nd informed consent before LVAD implantation and subsequent
ardiac transplantation.
The duration of support, survival, incidence of neurologic
omplications, device malfunctions, and infections were moni-
ored. Infections were defined as the presence of a positive blood
ulture along with a leukocytosis.
evices, Implant Procedure, and Anticoagulation
hree different systems of LVADs were used in the present
Abbreviations and Acronyms
LVAD left ventricular assist device
PG  prostaglandin
PH  pulmonary hypertension
PVR  pulmonary vascular resistance
WU Wood unitstudy. The technical details and implantation procedures of the 1
90 The Journal of Thoracic and Cardiovascular Surgery ● MarcicroMed DeBakey (MicroMed Technology Inc, Houston, Tex),
uraHeart (Terumo Heart Inc, Ann Arbor, Mich) (continuous
lood flow), and Novacor LVADs (World Heart Inc, Oakland,
alif) (pulsatile blood flow) have been described.18-20
Anticoagulation protocol was identical in all patients. During
xtracorporal circulation and implantation of the pump, patients
eceived intravenous heparin (300 U/kg body weight), and the
eart–lung machine was primed with 1,000,000 IU aprotinin. After
iscontinuation of extracorporal circulation, heparin was reversed
ith an appropriate dose of protamine. Intravenous heparin was
nstituted 6 hours after surgery to achieve activated partial throm-
oplastin target times of 50 to 60 seconds. Platelet anti-aggregation
herapy with 150 mg per day of aspirin and 225 mg per day of
ipyridamole was started after removal of all chest drains. Adminis-
ration of heparin was stopped when anticoagulation with coumarin
eached target levels of 2.5 to 3.5 international normalized ratio.
easurement of Pulmonary Hypertension
ight-sided heart catheterization was performed according to the
uidelines published by the American College of Cardiology/
merican Heart Association using a Swan–Ganz thermodilution
atheter. Right-sided heart catheterization was performed before
VAD implantation and 3 days and 6 weeks after LVAD implan-
ation.21 The PH variables assessed included PVR (Wood units),
ystolic pulmonary artery pressure (millimeters of mercury), mean
ulmonary artery pressure (millimeters of mercury), pulmonary cap-
llary wedge pressure (millimeters of mercury), and cardiac output
liters per minute). Cardiac output was measured with the Fick
ethod.
esting for Reversibility of Pulmonary Hypertension
H was defined as PVR greater than 3.5 WU. Reversibility of PH
as assessed by nitroglycerin, prostaglandin (PGI2), nitric oxide,
nd levosimendan (only available in the last 10 patients). Nitro-
lycerin was applied intravenously at increasing doses of 2 to 6 mg
er hour with dose increments every 10 minutes. PGI2 was given
ntravenously at increasing doses of 10 to 200 ng/kg/min with dose
ncrements every 5 minutes. Nitric oxide was administered in
oses of 40, 60, and 80 ppm through a tight-fitting facemask. In the
ast 10 patients, levosimendan was additionally used for testing for
eversibility of PH. If PH was not reversible with this treatment, it
as considered as fixed. All of the mentioned substances were
ested in all patients (Figure 1).
tatistical Analysis
ata are presented as frequency distributions and percentages.
alues of continuous variables are expressed as mean  standard
eviation. Continuous variables were compared using analysis of
ariance (Bonferroni). Categoric variables were compared by
eans of the chi-square or Fisher exact test as appropriate.
aplan–Meier analysis was used to calculate long-term survival
long with a log–rank P value when comparing groups. The study
as analyzed with the Statistical Package for the Social Sciences
1.5 (SPSS Inc, Chicago, Ill).
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Pesults
emographics
he characteristics of LVAD recipients are shown in Table 1.
he mean overall age was 56.6 years (88.5% were male).
ll patients were in New York Heart Association class IV
nd had fixed PH (PVR 5.1  2.8 WU) before LVAD
mplantation. Idiopathic cardiomyopathy was the most com-
on cause of heart failure present in 23 patients (65.5%),
nd ischemic cardiomyopathy was present in 12 patients
34.5%). Recipients of pulsatile and continuous flow LVAD
ere comparable with regard to patient characteristics
Table 1). Overall mechanical support time was 202  169
ays (range, 35-700 days).
urvival
wenty-four patients (69%) had successful bridges to
ransplantation (bridge to transplant time 210  83 days),
nd 11 patients (31%) died during LVAD support (sur-
ival time 67  30 days). One patient (5%) died after
ardiac transplantation. We found no difference in bridge
o transplant success between patients treated with pul-
atile (62.5%) or continuous flow (71.1%) LVAD (P 
igure 1. Pharmacologic testing: decision-making tree. TX, Trans-
lant; PVR, pulmonary vascular resistance; WU, Wood units; PG,
rostaglandin; NO, nitric oxide; LVAD, left ventricular assist
evice.147). One-year survival after cardiac transplantation was t
The Journal of Thoracic5%. The mean follow-up after cardiac transplantation
as 25  17 months. Overall survival is displayed in
igure 2.
ight-sided Heart Catheterization
efore LVAD implantation, PVR was 5.1  2.8 WU.
alues were comparable in patients receiving pulsatile
5.1  3.4 WU) and continuous blood flow LVADs (5.1 
.7 WU, P  .976). LVAD implantation decreased PVR at
-day (2.9  1.3 WU, P  .0001) and 6-week follow-ups
2.0  0.8 WU, P  .0001) compared with before implan-
ation. This effect was independent of the type of LVAD
ystem used (3-day follow-up: pulsatile flow 3.2  1.3 WU
s continuous flow 2.7  1.2 WU, P  .310; 6-week
ollow-up: pulsatile flow 1.9  0.9 WU vs continuous flow
.1  0.8 WU, P  .905). Detailed hemodynamic data are
hown in Table 2.
omplications and Causes of Death
he incidence and nature of complications and the causes of
eath are shown in Table 3. None of the patients required
echanical right-sided heart support after LVAD implanta-
ion. A total of 51.3% of patients experienced a complica-
ion while on LVAD support. Cerebrovascular events oc-
urred in 31% of patients, and infections occurred in 25.7%
f patients. We found no difference in the incidence and
ature of complications between patients treated with pul-
atile and continuous blood flow devices (Table 3). Cere-
rovascular events were the most common cause of death
resent in 45.4% of patients, followed by multiorgan failure
36.3%) and infections (18.3%). We found no difference in
he incidence and nature of complications between patients
reated with pulsatile and continuous blood flow devices
Table 3).
iscussion
evere fixed PH is a contraindication for cardiac transplan-
ation because of an increased risk of postoperative donor
eart failure. LVADs decrease fixed PH in cardiac trans-
lant candidates and enable them to undergo orthotopic
ardiac transplantation.
Pulmonary vascular hypertension is a common compli-
ation of severe long-standing heart failure. Approximately
2% of patients with terminal heart failure who are eligible
or cardiac transplantation have PH.22 The pathophysiology
ehind PH in patients with terminal heart failure is the result
f a multifactorial process mainly relating to left ventricular
ailure.23 Left atrial hypertension resulting from left ven-
ricular failure translates into increased postcapillary pres-
ure in the pulmonary circulation.23 This enhances pulmo-
ary endothelial dysfunction with decreased availability of
itric oxide and prostacyclin and increased production of
hromboxane A2 and endothelin-1.23 The activity of serine
and Cardiovascular Surgery ● Volume 133, Number 3 691
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CSPlastase is up-regulated in the subendothelium causing gly-
oprotein deposition and smooth muscle cell hypertrophy
nd hyperplasia.24 Intermittent hypoxia stimulates vasocon-
triction in the pulmonary vascular tree. Changes in the
xpression of von Willebrand factor result in the develop-
ent of platelet fibrin microthrombi.25 In addition, this
rocess is associated with smooth muscle cell hypertrophy
nd hyperplasia.23 Depending on the duration of these pro-
esses, remodeling of the pulmonary vascular tree takes
lace.
Fixed PH is considered to be present when elevated PVR
annot be significantly decreased (20%) by pharmaco-
ogic interventions.6,26 Although there is no international
onsensus, most transplant centers will not offer cardiac
ransplantation in patients with PVR greater than 3 to 4 WU
or the following reasons. In the case of cardiac transplan-
ation, the relatively thin-walled right ventricle of the organ
onor does not function adequately in the presence of ab-
ormally elevated PVR. This carries the high risk of dis-
ension of the donor right ventricle, resulting in right
entricular failure. In this case, neither high doses of
notropes nor mechanical support of the right ventricle
esults in a satisfying outcome.26-29 Posttransplant sur-
ival in patients with fixed PH is significantly worse
ompared with patients with normal PVR in both short and
ong-term follow-ups.3-7,29
In the present study, LVADs decreased fixed PH during
6-week period of support. PH in terminal heart failure, at
east in part, is the consequence of elevated left atrial filling
ABLE 1. Patient characteristics and heart failure therapy
ariable All patients
35
ge (y) 56.6 7
ale (%) 88.5
isease (CAD/ICM, %) 34.5/65.5
eight (kg) 80.4 12.2
eight (cm) 170 12
jection fraction (%) 18.2 6.3
OPD (%) 12.5
enal failure (%) 28.1
iabetes (%) 22.8
eart rate (beats/min) 95 7
OP (mm Hg) 90/60
eart failure (y) 5.3
iuretics (%) 100
eta-blockers (%) 94.5
CE inhibitor (%) 100
notropic support (%) 0
AD, Coronary artery disease; ICM, idiopathic cardiomyopathy; COPD, ch
iven); ACE, angiotensin-converting enzyme. Renal failure: defined as cr
Patients treated with continuous flow LVADs. †Patients treated with pulsaressures resulting from impaired left ventricular systolic L
92 The Journal of Thoracic and Cardiovascular Surgery ● Marcunction. Therefore, it might be speculated that LVADs
everse this process by continuously unloading the left
entricle. It remains to be studied whether LVAD support
esults in a reverse-remodeling of the pulmonary vascular
ree. Pulsatile and continuous blood flow LVADs equally
ecreased PH during a 6-week period of support. It was
reviously emphasized that left ventricular unloading is
ore efficiently done by continuous blood flow devices.30
his was based on the theoretic consideration that continu-
us blood flow devices unload the left ventricle during the
igure 2. Kaplan–Meier curve displaying overall survival after
nuous flow* Pulsatile flow† P value‡
27 8
.2 5 58.2 8 .853
92.5 87.5 .345
7.3/62.7 36.6/63.4 .679
.6 13.5 82.3 14.1 .872
2 9 171 6 .941
.9 7.3 18.3 8.2 .762
11.1 12.5 .928
22.2 37.5 .675
22.2 25.5 .314
3  8 96 6 .345
93/58 88/62 .476
5.5 5.1 .674
100 100 1.000
92.3 87.5 .429
100 100 1.000
0 0 1.000
obstructive pulmonary disease; AOP, aortic pressure (only mean values
e  2.0 mg/dL (177 mol/L). Heart failure (y): duration of heart failure.
ow LVADs. ‡P value: continuous flow LVADs versus pulsatile flow LVADs.Conti
54
3
78
17
17
9
ronic
eatininVAD implantation.
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Phole cardiac circle. On the basis of this finding, the deci-
ion for the type of LVAD in cardiac transplant candidates
ith fixed PH should depend only on the patient’s demands.
specially in large patients, the flow provided by continu-
us flow LVADs may be too low to increase exercise
olerance and enable recovery of the patient.31
Compared with the high risk of donor heart failure in
atients with fixed PH and orthotopic cardiac transplanta-
ion, the combined approach of LVAD support and subse-
uent cardiac transplantation seems promising. Successful
ridging rates ranging from 65% to 70% have been reported
n patients without PH.32 We successfully bridged 69% of
atients to safe cardiac transplantation. Posttransplant sur-
ivals at 30-day (95%) and 12-month (95%) follow-ups
ere comparable to those reported in patients without PH at
he time of cardiac transplantation.33 Because of these
esults, all cardiac transplant candidates with a PVR
reater than 3.5 WU (after testing for reversibility) re-
eive an LVAD before cardiac transplantation at our
enter. Alternative approaches to orthotopic cardiac
ABLE 2. Data from right-sided heart catheterization
ariable All patients P value*
35
VR
Baseline 5.1 2.6 —
3-d FUP 2.9 1.3 .0001
6-wk FUP 2.0 0.8 .0001
After testing 4.5 2.1 —
Asyst
Baseline 63.2 9.3 —
3-d FUP 39.6 10.6 .0001
6-wk FUP 26.7 3.6 .0001
After testing 36 10.2 —
Amean
Baseline 44.0 6.2 —
3-d FUP 28.6 7.3 .0001
6-wk FUP 18.4 4.3 .0001
After testing 30.2 6.8 —
CWP
Baseline 28.1 6.0 —
3-d FUP 12.0 5.7 .0001
6-wk FUP 10.0 3.6 .0001
After testing 15.8 1.9 —
O
Baseline 3.1 0.8 —
3-y FUP 5.7 0.7 .0001
6-wk FUP 4.0 0.9 .002
After testing 3.2 7 —
VR, Pulmonary vascular resistance (WU); FUP, follow-up; PAsyst, systolic
mm Hg); PCWP, pulmonary capillary wedge pressure (mm Hg); CO, cardiac
reated with continuous flow LVADs. ‡Patients treated with pulsatile flow L
emodynamic data immediately before LVAD implantation. After testing: hransplantation, such as heterotopic cardiac transplanta- i
The Journal of Thoracicion and right ventricle-sparing transplant techniques, have
een recommended in the past in patients with severe
H.34,35 In these select cases, the donor heart acts as a
iological assist device to the native left ventricle or both
entricles. Survivals reported at 12-month follow-ups range
etween 83% and 59%.34,35 The major limitations of hete-
otopic transplantation are the availability of a suitable
onor, technical difficulties during implantation, and, in
articular, late interactions of donor and recipient heart.36
urvivals with these alternative approaches are significantly
ower compared with LVAD implantation and subsequent
rthotopic cardiac transplantation. The presented algorithm
ignificantly reduces the incidence of right-sided heart fail-
re after cardiac transplantation to less than 1% and is
ssociated with good posttransplant survival.
Nevertheless, patient morbidity while on LVAD support
till remains a major concern, because 51% of all patients
xhibited a severe adverse event. Most common were neuro-
ogic events, which also significantly contributed to patient
ortality on LVAD support. Other complications included
Continuous flow† Pulsatile flow‡ P value§
27 8
5.3 2.7 5.1  3.5 .976
2.7 1.2 3.2  1.3 .310
2.1 0.8 1.9  0.9 .905
— — —
65.2 13.0 65.3 10 .976
37.6 9.4 43.4 12.5 .175
29.6 6.5 28.1 7.5 .236
— — —
45.5 6.8 43.0 8.4 .397
28.1 7.5 29.6 6.5 .604
19.0 4.2 17.8 5.1 .571
— — —
29.0 5.7 27.1 7.0 .439
11.9 4.4 13.0 8.3 .641
10.1 13.7 9.1 3.7 .572
— — —
3.0  0.6 2.6  0.7 .601
6.2 1.1 5.1  0.8 .375
4.2 0.8 4.6  0.4 .453
— — —
onary artery pressure (mm Hg); PAmean, mean pulmonary artery pressure
ut (lxmin1). *P value: compared with before LVAD implantation. †Patients
. §P value: continuous flow LVADs versus pulsatile flow LVADs. Baseline:
ynamic data after pharmacologic testing.pulm
outp
VADsnfections and bleeding. No device-related complications were
and Cardiovascular Surgery ● Volume 133, Number 3 693
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CSPbserved. In our series the incidence of adverse events com-
ares with that reported by others.37,38 There was no differ-
nce in adverse events between pulsatile and continuous
ow LVADs. Continuous research, improvement of de-
ices, and careful patient selection are crucial to reduce
VAD-associated complications.
onclusions
he primary limitation of the present study is the nonran-
omized design. The reason for this design is because fixed
H is a contraindication for cardiac orthotopic transplan-
ation. Therefore, comparing cardiac transplantation with
nd without prior LVAD implantation would be ethically
uestionable.
LVADs decrease fixed PH in cardiac transplant candi-
ates and allow them to overcome fixed PH as a contrain-
ication for cardiac transplantation. Therefore, LVADs
hould be considered in all cardiac transplant candidates
ith fixed PH.
We thank Daniela Dunkler, MSc, from the Institute of Medical
iometry, Medical University of Vienna, for assistance with the
tatistical analysis.
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